Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies

Clinical Therapeutics

Volumn 29, Issue 11 SUPPL. 1, 2007, Pages 2536-2546

  Kajdasz, Daniel K ^a   Iyengar, Smriti ^a   Desaiah, Durisala ^a   Backonja, Misha Miroslav ^b   Farrar, John T ^c   Fishbain, David A ^d   Jensen, Troels S ^e   Rowbotham, Michael C ^f   Sang, Christine N ^g   Ziegler, Dan ^h   McQuay, Henry J ⁱ  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

diabetic peripheral neuropathic pain; duloxetine; neuropathy; NNH; NNT

Indexed keywords

DULOXETINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MULTICENTER STUDY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PHYSICIAN; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 37349086775     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.002     Document Type: Article

References (42)

1. Fields H., and Basbaum A. Central nervous system mechanisms of pain modulation. In: Wall P., and Melzack R. (Eds). Textbook of Pain. 3rd ed. (1994), Churchill Livingstone, New York, NY 243-257
2. Max M., Lynch S., Muir J., et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 (1992) 1250-1256
3. Sindrup S., Bach F., Madsen C., et al. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 60 (2003) 1284-1289
4. Detke M., Lu Y., Goldstein D., et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63 (2002) 308-315
5. Detke M., Lu Y., Goldstein D., et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 36 (2002) 383-390
6. Goldstein D., Mallinckrodt C., Lu Y., and Demitrack M. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 63 (2002) 225-231
7. Goldstein D., Lu Y., Detke M., et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45 (2004) 17-28
8. Goldstein D., Lu Y., Detke M., et al. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24 (2004) 389-399
9. Goldstein D., Lu Y., Detke M., et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
10. Raskin J., Pritchett Y., Wang F., et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6 (2005) 346-356
11. Wernicke J., Pritchett Y., D'Souza D., et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 (2006) 1411-1420
12. Laupacis A., Sackett D., and Roberts R. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988) 1728-1733
13. McQuay H., and Moore R. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126 (1997) 712-720
14. Altman D., and Andersen P. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319 (1999) 1492-1495
15. Katona C., and Livingston G. How well do antidepressants work in older people? A systematic review of number needed to treat. J Affect Disord 69 (2002) 47-52
16. Nuovo J., Melnikow J., and Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 287 (2002) 2813-2814
17. Trainer M., and Walder B. Number needed to treat (or harm). World J 5urg 29 (2005) 576-581
18. Feldman E., Stevens M., Thomas P., et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17 (1994) 1281-1289
19. Cook R., and Sackett D. The number needed to treat: A clinically useful measure of treatment effect. [published correction appears in BMJ. 1995;310:1056]. BMJ 310 (1995) 452-454
20. Rajkumar S., Sampathkumar P., and Gustafson A. Number needed to treat is a simple measure of treatment efficacy for clinicians. J Gen Intern Med 11 (1996) 357-359
21. Cookson J., Gilaberte I., Desaiah D., and Kajdasz D. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 21 (2006) 267-273
22. Moore A., McQuay H., and Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain 66 (1996) 229-237
23. Farrar J., Portenoy R., Berlin J., et al. Defining the clinically important difference in pain outcome measures. Pain 88 (2000) 287-294
24. McQuay H., Carroll D., Jadad A., et al. Anticonvulsant drugs for management of pain: A systematic review. BMJ 311 (1995) 1047-1052
25. Moher D., Jadad A., Nichol G., et al. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Control Clin Trials 16 (1995) 62-73
26. Sindrup S., and Jensen T. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
27. Sindrup S., and Jensen T. Pharmacologic treatment of pain in polyneuropathy. Neurology 55 (2000) 915-920
28. Finnerup N., Otto M., McQuay H., et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 118 (2005) 289-305
29. Attal N., Cruccu G., Haanpaa M., et al., for the EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13 (2006) 1153-1169
30. Wong M., Chung J., and Wong T. Effects of treatments for symptoms of painful diabetic neuropathy: Systematic review. BMJ 335 (2007) 87
31. Leinonen E., Lepola U., Koponen H., et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 96 (1997) 497-504
32. Sauer H., Huppertz-Helmhold S., and Dierkes W. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry 36 (2003) 169-175
33. Nelson K., Park K., Robinovitz E., et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48 (1997) 1212-1218
34. Sang C., Booher S., Gilron I., et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology 96 (2002) 1053-1061
35. Rowbotham M., Goli V., Kunz N., and Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. [published correction appears in Pain. 2005;113:248]. Pain 110 (2004) 697-706
36. Tolle T., Freynhagen R., Versavel M., et al. A randomized, double-blind, placebo-controlled study evaluating twice daily dosing of pregabalin for relief of neuropathic pain associated with diabetic peripheral neuropathy. Eur J Pain (July 13, 2007) Epub
37. Wernicke J., Lledo A., Raskin J., et al. An evaluation of the cardiovascular safety profile ofduloxetine: Findings from 42 placebo-controlled studies. Drug Saf. 30 (2007) 437-455
38. Detsky A., Naylor C., O'Rourke K., et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 45 (1992) 255-265
39. Moher D., Cook D., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
40. Alderson P., Green S., and Higgins J. Cochran Reviewers' Handbook 4.2.2 (2003), John Wiley & Sons, Ltd, Chichester, UK
41. Altman D., and Deeks J. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2 (2002) 3
42. Moore I., Gavaghan D., Edwards J., et al. Pooling data for number needed to treat: No problems for apples. BMC Med Res Methodol 2 (2002) 2